AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14696661 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable membrane (MR group)
Number of subjects: 83
Study 14696661 — intervention group
Group type: COMPARATOR
Intervention: Both HA and MR groups combined
Number of subjects: 83
Study 11139755 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (ibuprofen 400-800mg, naproxen 550-825mg, ketoprofen 50-75mg)
Number of subjects: 0
Study 11139755 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing preparations of NSAIDs
Number of subjects: 0
Study 11139755 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapies with EMG biofeedback and tricyclics
Number of subjects: 0
Study 11139755 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy and acupuncture
Number of subjects: 0
Study 8864328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 240 mg i.v. once daily for 7 days
Number of subjects: 12
Study 8864328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1623916 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide (1 to 16 mg)
Number of subjects: 10
Study 6391141 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg twice weekly for 1 year)
Number of subjects: 251
Study 6391141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 6391141 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 251
Study 6391141 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole among responders
Number of subjects: 251
Study 6391141 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo among responders
Number of subjects: 251
Study 31801531 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Patients (VP)
Number of subjects: 57
Study 31801531 — intervention group
Group type: COMPARATOR
Intervention: Small Group Teaching (SGT)
Number of subjects: 57
Study 29985774 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional warm-up protocol (functional stretching, stability, and mobility exercises)
Number of subjects: 120
Study 29985774 — intervention group
Group type: COMPARATOR
Intervention: Traditional dynamic warm-up
Number of subjects: 120
Study 26825878 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Albendazole (L‐ABZ), 10 mg/kg per day, p.o., b.i.d.
Number of subjects: 60
Study 26825878 — intervention group
Group type: COMPARATOR
Intervention: Tablet-Albendazole (T‐ABZ), 12-20 mg/kg per day, p.o., b.i.d.
Number of subjects: 60
Study 26825878 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (L‐ABZ and T‐ABZ)
Number of subjects: 60
Study 24458439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 166
Study 24458439 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 166
Study 22476173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal leukocytes test performed (Group A)
Number of subjects: 201
Study 22476173 — intervention group
Group type: COMPARATOR
Intervention: Fecal leukocytes test and rotavirus/adenovirus test performed (Group B)
Number of subjects: 201
Study 20578811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER 100 ‐ 250 mg b.i.d.
Number of subjects: 981
Study 20578811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone CR 20 ‐ 50 mg b.i.d.
Number of subjects: 981
Study 20578811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study 18624029 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 16116009 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular block
Number of subjects: 80
Study 16116009 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular block
Number of subjects: 80
Study 16116009 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 12352272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (15-mg nicotine patch, 4-mg nicotine gum, 10-mg nicotine inhaler, or combination)
Number of subjects: 923
Study 12352272 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo products
Number of subjects: 923
Study 12352272 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 923
Study 12352272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine group
Number of subjects: 923
Study 12352272 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 923
Study 12352272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 923
Study 10425011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion during cardiopulmonary bypass (group 2)
Number of subjects: 22
Study 10425011 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion during cardiopulmonary bypass (group 1)
Number of subjects: 22
Study 7750335 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 100
Study 7750335 — intervention group
Group type: COMPARATOR
Intervention: Control (face‐mask oxygen therapy)
Number of subjects: 100
Study 2184356 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2b (n = 50)
Number of subjects: 101
Study 2184356 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n = 51)
Number of subjects: 101
Study 7292376 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg twice daily for three weeks
Number of subjects: 19
Study 7292376 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the first week
Number of subjects: 19
Study 31197389 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic Broström repair technique (ABR)
Number of subjects: 61
Study 31197389 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lateral ligaments augmentation using suture-tape internal bracing (AST)
Number of subjects: 61
Study 30860492 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Healthy, Stay Healthy (GHSH) intervention, n=114
Number of subjects: 228
Study 30860492 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no additional contact), n=114
Number of subjects: 228
Study 28192551 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support system (T2D module)
Number of subjects: 1369
Study 28192551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no T2D module)
Number of subjects: 1369
Study 27136907 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq. (156 mg of PP) administered via deltoid injections
Number of subjects: 49
Study 27136907 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate 100 mg eq. (156 mg of PP) administered via gluteal injections
Number of subjects: 49
Study 23262383 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 99
Study 23262383 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 99
Study 23262383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 99
Study 21991738 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suprascapular nerve block under ultrasound guidance plus rehabilitation program
Number of subjects: 50
Study 21991738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection plus rehabilitation program
Number of subjects: 50
Study 21991738 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation program only
Number of subjects: 50
Study 19210144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean common CIMT protocols measuring both near and far wall at >= 2 angles
Number of subjects: 675
Study 19210144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean maximum protocol measuring three segments at >= 2 angles
Number of subjects: 675
Study 19210144 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 675
Study 19210144 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate scans
Number of subjects: 675
Study 16019102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management (NCM)
Number of subjects: 332
Study 16019102 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary care provider
Number of subjects: 332
Study 12615585 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (1.5 micro g/kg)
Number of subjects: 50
Study 12615585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (1.5 micro g/kg)
Number of subjects: 50
Study 10848718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg daily for 8 days)
Number of subjects: 7
Study 10848718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9313642 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS over supplementary motor area
Number of subjects: 15
Study 9313642 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS over primary motor cortex
Number of subjects: 15
Study 9313642 — intervention group
Group type: COMPARATOR
Intervention: rTMS over other positions (e.g. F3, F4, FCz, P3, P4)
Number of subjects: 15
Study 8371727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest
Number of subjects: 171
Study 8371727 — intervention group
Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass
Number of subjects: 171
Study 2878130 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation with six courses of DAT (daunorubicin, cytarabine, and 6-thioguanine)
Number of subjects: 1127
Study 2878130 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification with cyclophosphamide, vincristine, cytarabine, and prednisolone (COAP)
Number of subjects: 1127
Study 2878130 — intervention group
Group type: COMPARATOR
Intervention: CNS prophylaxis with intrathecal cytarabine and methotrexate
Number of subjects: 1127
Study 2878130 — intervention group
Group type: EXPERIMENTAL
Intervention: Histocompatible allogeneic bone-marrow transplants in first remission
Number of subjects: 1127
Study 2878130 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment during the trial
Number of subjects: 1127
Study 31350814 — intervention group
Group type: EXPERIMENTAL
Intervention: Purgenesis™ Day Cream, Purgenesis™ Eye Cream, and Purgenesis™ Night Cream
Number of subjects: 72
Study 31350814 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevage® Eye Lotion, Prevage® Day Cream, and Prevage® Night Cream
Number of subjects: 72
Study 31350814 — intervention group
Group type: EXPERIMENTAL
Intervention: La Mer® Eye Balm, Crème de La Mer®, and La Mer® Night Cream
Number of subjects: 72
Study 31350814 — intervention group
Group type: COMPARATOR
Intervention: Group B (Prevage®)
Number of subjects: 72
Study 29494818 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel 135 mg/m2 day 1 and cisplatin 20 mg/m2 days 1‐3, every 4 weeks) plus erlotinib (150 mg per day during chemoradiotherapy)
Number of subjects: 352
Study 29494818 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy
Number of subjects: 352
Study 29494818 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy plus erlotinib
Number of subjects: 352
Study 29494818 — intervention group
Group type: COMPARATOR
Intervention: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy
Number of subjects: 352
Study 29494818 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nodal irradiation (ENI)
Number of subjects: 352
Study 29494818 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 352
Study 26810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 50
Study 26810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 50
Study 24374549 — intervention group
Group type: EXPERIMENTAL
Intervention: Semuloparin 20 mg commenced postoperatively
Number of subjects: 4413
Study 24374549 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg commenced preoperatively
Number of subjects: 4413
Study 23340895 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI 20 min
Number of subjects: 100
Study 23340895 — intervention group
Group type: COMPARATOR
Intervention: No IMI
Number of subjects: 100
Study 20602568 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + Asc (2 l PEG + ascorbic acid)
Number of subjects: 350
Study 20602568 — intervention group
Group type: COMPARATOR
Intervention: PEG (4 l PEG solution)
Number of subjects: 350
Study 17631877 — intervention group
Group type: EXPERIMENTAL
Intervention: Typicality effect in sentence production
Number of subjects: 0
Study 17631877 — intervention group
Group type: COMPARATOR
Intervention: Ad hoc categories
Number of subjects: 0
Study 17631877 — intervention group
Group type: EXPERIMENTAL
Intervention: Carefully matched sentences with two category members
Number of subjects: 0
Study 16633762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (SEV, n = 31)
Number of subjects: 61
Study 16633762 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol, fentanyl, and vecuronium anesthesia (TIVA, n = 30)
Number of subjects: 61
Study 16633762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (SEV)
Number of subjects: 61
Study 16633762 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol, fentanyl, and vecuronium anesthesia (TIVA)
Number of subjects: 61
Study 14749744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheep's dairy fat
Number of subjects: 41
Study 14749744 — intervention group
Group type: COMPARATOR
Intervention: Cows' dairy fat
Number of subjects: 41
Study 11729013 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of paroxetine
Number of subjects: 551
Study 11729013 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day of paroxetine
Number of subjects: 551
Study 11729013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 9845027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation before schooling
Number of subjects: 121
Study 9845027 — intervention group
Group type: COMPARATOR
Intervention: Cochlear implantation during educational placement
Number of subjects: 121
Study 7837157 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OA of the knee
Number of subjects: 48
Study 7837157 — intervention group
Group type: COMPARATOR
Intervention: Subjects without OA of the knee
Number of subjects: 48
Study 3069498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial instillation of 0.5 mg reserpine
Number of subjects: 50
Study 3069498 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 50
Study 29316715 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-Intensity Continuous Training (MIT, n = 21, 60% of VO2max)
Number of subjects: 41
Study 29316715 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT, n = 20, 100-200% of VO2max)
Number of subjects: 41
Study 29316715 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 41
Study 26777329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stenting (SES)
Number of subjects: 200
Study 26777329 — intervention group
Group type: COMPARATOR
Intervention: Plain Balloon Angioplasty (PTA)
Number of subjects: 200
Study 25911281 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD checkers
Number of subjects: 0
Study 25911281 — intervention group
Group type: COMPARATOR
Intervention: OCD washers
Number of subjects: 0
Study 25911281 — intervention group
Group type: COMPARATOR
Intervention: Non-patients
Number of subjects: 0
Study 23632034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat labeling with caloric information
Number of subjects: 175
Study 23632034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat labeling
Number of subjects: 175
Study 23632034 — intervention group
Group type: COMPARATOR
Intervention: Regular-labeled candy
Number of subjects: 175
Study 21070720 — intervention group
Group type: EXPERIMENTAL
Intervention: PEPAF (program promoting physical activity)
Number of subjects: 3698
Study 21070720 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3698
Study 19008680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-linguistic treatment
Number of subjects: 58
Study 16785475 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg body weight, once-monthly infusion)
Number of subjects: 652
Study 12697204 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional intervention
Number of subjects: 271
Study 12697204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined motivational plus volitional intervention
Number of subjects: 271
Study 12697204 — intervention group
Group type: COMPARATOR
Intervention: Motivational intervention
Number of subjects: 271
Study 12697204 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 271
Study 10955205 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 treatment groups with different kinds of tutor modeling (whole word, letter-phoneme, combined whole word and letter-phoneme)
Number of subjects: 128
Study 10955205 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole word, letter-phoneme, and combined whole word and letter-phoneme modeling
Number of subjects: 128
Study 10955205 — intervention group
Group type: COMPARATOR
Intervention: Contact control group that received phonological and orthographic awareness training without explicit instruction on orthographic-phonological connections
Number of subjects: 128
Study 9361342 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) supplementation for 14 days
Number of subjects: 40
Study 9361342 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 8251355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg at night
Number of subjects: 19
Study 8251355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3513564 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol
Number of subjects: 20
Study 3513564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metaproterenol
Number of subjects: 20
Study 3513564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inhaled and oral metaproterenol
Number of subjects: 20
Study 31655485 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50 mg)
Number of subjects: 40
Study 31655485 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 29727794 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical demonstration video
Number of subjects: 0
Study 29727794 — intervention group
Group type: COMPARATOR
Intervention: Practitioner role play video
Number of subjects: 0
Study 29727794 — intervention group
Group type: COMPARATOR
Intervention: Clinical demonstration video (Phase 2)
Number of subjects: 0
Study 29727794 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical demonstration video (Phase 3)
Number of subjects: 0
Study 27508274 — intervention group
Group type: EXPERIMENTAL
Intervention: COH + TS + chlorhexidine + probiotics (Group D)
Number of subjects: 208
Study 27508274 — intervention group
Group type: EXPERIMENTAL
Intervention: COH + TS + chlorhexidine (Group C)
Number of subjects: 208
Study 27508274 — intervention group
Group type: COMPARATOR
Intervention: COH (Group A)
Number of subjects: 208
Study 27508274 — intervention group
Group type: COMPARATOR
Intervention: COH + tongue scraping (Group B)
Number of subjects: 208
Study 24691452 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI with renal denervation (RD)
Number of subjects: 86
Study 24691452 — intervention group
Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 86
Study 22455564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (AIT)
Number of subjects: 31
Study 22455564 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 31
Study 22455564 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 20357664 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 132
Study 20357664 — intervention group
Group type: COMPARATOR
Intervention: SNRIs (duloxetine and venlafaxine)
Number of subjects: 132
Study 19014549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 800 microg QD PM
Number of subjects: 911
Study 19014549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 400 microg BID
Number of subjects: 911
Study 19014549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study 19014549 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled MF‐DPI groups
Number of subjects: 911
Study 15824294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training for 6 months
Number of subjects: 104
Study 15824294 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical activity and diet advice (Control)
Number of subjects: 104
Study 12854895 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-HC (high dose cyclophosphamide consolidation)
Number of subjects: 25
Study 12854895 — intervention group
Group type: COMPARATOR
Intervention: CHOP (control)
Number of subjects: 25
Study 12854895 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-HC
Number of subjects: 25
Study 12854895 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 25
Study 10536557 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.9 mg kg‐1
Number of subjects: 30
Study 10536557 — intervention group
Group type: COMPARATOR
Intervention: succinylcholine 1.5 mg kg‐1
Number of subjects: 30
Study 10536557 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 30
Study 8671562 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled intervention to reduce unjustified hospital stay days (HSD)
Number of subjects: 155
Study 8671562 — intervention group
Group type: COMPARATOR
Intervention: Control ward (N=248)
Number of subjects: 155
Study 8671562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both wards (study and control)
Number of subjects: 155
Study 2016626 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-n1 alone
Number of subjects: 165
Study 2016626 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-n1 with vinblastine
Number of subjects: 165